Nivolumab, a PD-1 inhibitor, achieved an objective response rate of 40.0% in patients with melanoma without the Braf mutation, 19% in non-small-cell lung cancer (NSCLC), and 66.3–87% in Hodgkin lymphoma (Ansell et al., 2015; Borghaei et al., 2015; Robert et al., 2015; Younes et al., 2016). Here, PDCD1 is linked to non-small cell lung carcinoma.